- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04923347
A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)
May 17, 2024 updated by: GlaxoSmithKline
Phase IV, 12-week, Single Arm, Open Label Study Evaluating the Safety and Efficacy of Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning Via a Dry Powder Inhaler in Participants With Chronic Obstructive Pulmonary Disease in India
This study will evaluate safety and efficacy of FF/UMEC/VI via ELLIPTA® inhaler.
ELLIPTA is a registered trademark of GlaxoSmithKline group of companies.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
229
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ajmer, India, 305001
- GSK Investigational Site
-
Bikaner, India, 334001
- GSK Investigational Site
-
Hyderabad, India, 500084
- GSK Investigational Site
-
Jaipur, India, 302039
- GSK Investigational Site
-
Kolkata, India, 700014
- GSK Investigational Site
-
Kolkata, India, 700027
- GSK Investigational Site
-
Kozhikode, India, 673008
- GSK Investigational Site
-
Mumbai, India, 401107
- GSK Investigational Site
-
Mysuru, India, 57001
- GSK Investigational Site
-
Nagpur, India, 44009
- GSK Investigational Site
-
Nashik, India, 422007
- GSK Investigational Site
-
Pune, India, 411047
- GSK Investigational Site
-
-
Karnataka
-
Bangalore, Karnataka, India, 560092
- GSK Investigational Site
-
-
Tamil Nadu State
-
Pillaiyarkuppam, Pondicherry, Tamil Nadu State, India, 605402
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion criteria:
- A signed and dated written informed consent prior to study participation
- Participants 40 years of age or older at Screening (Visit 1)
- Male and female participants will be included in the study. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to follow the contraceptive guidance during the treatment period and until the safety follow-up contact after the last dose of study intervention.
- An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society.
- Current or former cigarette smokers with a history of cigarette smoking of greater than equal to (>=)10 pack-years at Screening (Visit 1) (number of pack years = [number of cigarettes per day divided by 20] times number of years smoked [for example 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years]). Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1.
- Participant with history of >=2 moderate exacerbations or one severe (hospitalized) exacerbation in the previous 12 months, and with a score of >=10 on the COPD Assessment Test (CAT) eligible for the study treatment in the opinion of the investigator and documented post salbutamol FEV1/ Forced Vital Capacity (FVC) ratio of <0.70
- Participant must be receiving daily long-acting maintenance treatment for their COPD for at least 3 months prior to Screening. To be eligible for the study treatment phase, participants must be compliant with their existing COPD maintenance therapy (in the opinion of the investigator) for the preceding two weeks prior to screening.
- A negative test for active Coronavirus Disease 2019 (COVID-19) at Visit 1. The test should be done using a molecular (Polymerase chain reaction [PCR] or antigen test) approved by the country regulatory authorities.
Exclusion Criteria:
- Women who are pregnant or lactating or are planning on becoming pregnant during the study.
- Participants with a current diagnosis of asthma. (Participants with a prior history of asthma are eligible if they have a current diagnosis of COPD).
- Documented (medical records) evidence of reversibility. Reversibility is defined as an increase in FEV1 of >=12 percent (%) and >=200 milliliter (mL) following administration of salbutamol. Participants defined as non-reversible will have a post-salbutamol increase in FEV1 of <200mL or a >=200mL increase that is <12% from pre-salbutamol baselineParticipants with alpha 1-antitrypsin deficiency as the underlying cause of COPD.
- Participants with active tuberculosis, lung cancer, and clinically significant (in the opinion of the investigator): bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
- Participants with lung volume reduction surgery within the 12 months prior to Screening
- Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 14 days prior to Screening and at least 30 days following the last dose of oral/systemic corticosteroids and/or antibiotics (if applicable). In addition, any participant that experiences pneumonia and/or moderate or severe COPD exacerbation within the preceding two weeks prior to screening will be excluded.
- Respiratory tract infection that has not resolved at least 7 days prior to Screening.
- Participants with known COVID-19 positive contacts within the past 14 days should be excluded for at least 14 days since the exposure and the participant remains symptom free. Participants with symptoms suggestive of active COVID-19 infection e.g. fever, cough (new or worsened), etc. are also excluded.
- Chest x-ray (poster anterior and lateral) reveals evidence of pneumonia or a clinically significant abnormality not believed to be due to the presence of COPD, or another condition that would hinder the ability to detect an infiltrate on chest x-ray (CXR) (e.g. significant cardiomegaly, pleural effusion or scarring).
- Participants with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled.
- Abnormal and clinically significant 12-lead electrocardiogram (ECG) finding at Visit 1.
- Use of long-term oxygen therapy (LTOT) described as resting oxygen therapy >3 Liters per minute (L/min) at screening (Oxygen use <=3L/min flow at rest is not exclusionary.)
- Participants must not start the acute phase of a pulmonary rehabilitation program within the 4 weeks prior to Visit 1.
- Participants who are medically unable to withhold their salbutamol for the 4-hour period required prior to spirometry testing at each study visit.
- In the opinion of the investigator, any participant who is unable to read and/or would not be able to complete study related materials.
- Use of the following medications within the following time intervals prior to Visit 1 or during the study:
- Participants receiving antibiotics for long term therapy are not eligible for the study.
- No use of systemic, Oral, parenteral corticosteroids within 30 days prior to screening (Intra-articular injections are allowed).
- No use of any other investigational drug within 30 days or 5 half-lives whichever is longer prior to screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Participants receiving FF/UMEC/VI via ELLIPTA inhaler
|
FF/UMEC/VI will be administered
Participants will receive FF/UMEC/VI using ELLIPTA inhaler.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events (AE), serious adverse events (SAE) and adverse events of special interest (AESIs)
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change from Baseline in trough forced expiratory volume in 1 second (FEV1) at Days 28, 85
Time Frame: Baseline (Day 1) and at Days 28, 85
|
Baseline (Day 1) and at Days 28, 85
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 6, 2023
Primary Completion (Actual)
March 14, 2024
Study Completion (Actual)
March 14, 2024
Study Registration Dates
First Submitted
June 6, 2021
First Submitted That Met QC Criteria
June 6, 2021
First Posted (Actual)
June 11, 2021
Study Record Updates
Last Update Posted (Actual)
May 17, 2024
Last Update Submitted That Met QC Criteria
May 17, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 212655
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal.
Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD Sharing Time Frame
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD Sharing Access Criteria
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on FF/UMEC/VI
-
GlaxoSmithKlineRecruitingAsthmaUnited States, Australia, Argentina, Korea, Republic of, Mexico, Turkey, Chile
-
GlaxoSmithKlineRecruiting
-
GlaxoSmithKlineParexelCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveChina
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Argentina, Germany, Poland, Romania, Russian Federation, Ukraine
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Argentina, Chile, Romania, Canada
-
GlaxoSmithKlineCompletedAsthmaAustralia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveChina